# Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients

> **NCT04638491** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Lurbinectedin for injection

## Key facts

- **NCT ID:** NCT04638491
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-24
- **Primary completion:** 2023-11-04
- **Final completion:** 2023-11-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04638491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04638491, "Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04638491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*